Preliminary Final Report and Annual Report YE 31 March 2024
Filed with ASX · · 75 pages · English
This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics. Investor Contact: Dr Chris Burns Media Contact: H^CK Director, Haley Chartres Chief Executive Officer haley@hck.digital chris@ampliatx.com +61 423 139 163 About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinas
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- $4.27m Offer Successfully Completed and ACCENT Trial Update
- Rights Issue Investor Slide Deck
- Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27
- Update on ACCENT Trial in Pancreatic Cancer
- FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US
Later from Amplia Therapeutics
- First 26 Patients recruited in Phase 2A ACCENT Trial
- Sustained Reduction in Tumour Size Seen In Pancreatic Trial
- Additional Patient Response in Pancreatic Cancer Trial
- Granting of Key Patent in Europe and Japan
- Amplia Receives R&D Tax Rebate Totalling $3.2 Million
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics